Regeneron Pharmaceuticals, Inc.
REGN
Market Cap$105.85B
Close$
Earnings Call Q4 2023
February 2, 2024 - AI Summary
Regeneron had a strong performance in 2023, with significant achievements such as the successful launch of EYLEA HD and continued growth of Dupixent and Libtayo.
The company is focused on driving commercial execution, including accelerating the conversion of patients to EYLEA HD and expanding the use of Dupixent in new indications like eosinophilic COPD.
In oncology, Regeneron has several potential launches planned for 2024, including odronextamab and linvoseltamab, which have the potential to be best-in-class bispecific antibodies.
Exclusive for Stockcircle Pro members
Sign up
$2059.79
112.4% upside
Current Fair Value
112.4% upsideUndervalued by 112.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $105.85 Billion |
|---|---|
| Enterprise Value | $98.03 Billion |
| Dividend Yield | $0.0 (0.0%) |
| Earnings per Share | $33.85 |
| Beta | 0.48 |
| Outstanding Shares | 107,943,750 |
| Avg 30 Day Volume | 444,040 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 27.44 |
|---|---|
| PEG | -234.22 |
| Price to Sales | 8.02 |
| Price to Book Ratio | 3.88 |
| Enterprise Value to Revenue | 7.48 |
| Enterprise Value to EBIT | 24.49 |
| Enterprise Value to Net Income | 25 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.1 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Regeneron Pharmaceuticals, Inc.
CEO: Leonard Schleifer